This afternoon we watched Nuvalent rise 13.2% to a price of $109.25 per share. The Mid-Cap Pharmaceutical company is now trading -14.1% below its average target price of $127.19. Analysts have set target prices ranging from $112.0 to $155.0 per share for Nuvalent, and have given the stock an average rating of buy.
The stock has an above average percentage of its shares sold short at 14.8%, and a short ratio of 8.33. Since 2.74% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 110.2% of Nuvalent's shares being owned by this investor type.
Institutions Invested in Nuvalent
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-09-30 | Deerfield Management Company, L.P | 27% | 17,991,024 | $1,965,609,277 |
| 2025-09-30 | FMR, LLC | 15% | 10,013,237 | $1,093,996,180 |
| 2025-09-30 | Paradigm Biocapital Advisors LP | 8% | 5,269,433 | $575,711,887 |
| 2025-09-30 | Vanguard Group Inc | 7% | 4,605,007 | $503,120,027 |
| 2025-09-30 | Blackrock Inc. | 6% | 4,085,795 | $446,393,521 |
| 2025-09-30 | Wellington Management Group, LLP | 3% | 2,300,865 | $251,380,999 |
| 2025-09-30 | Janus Henderson Group PLC | 3% | 2,188,674 | $239,123,571 |
| 2025-09-30 | Price (T.Rowe) Associates Inc | 3% | 1,810,420 | $197,797,432 |
| 2025-09-30 | JPMORGAN CHASE & CO | 2% | 1,674,009 | $182,893,848 |
| 2025-09-30 | State Street Corporation | 2% | 1,574,747 | $172,048,979 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Nuvalent.
